Does an alpha‑1‑antitrypsin level of 249 mg/dL indicate deficiency, and what further evaluation or treatment is needed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Alpha-1-Antitrypsin Level of 249 mg/dL: Interpretation and Management

Direct Answer

An alpha-1-antitrypsin level of 249 mg/dL is within the normal range and does not indicate deficiency in most clinical scenarios, but further evaluation with DNA sequencing of the SERPINA1 gene is warranted if you have high clinical suspicion based on specific risk factors. 1

Understanding the Result

Your A1AT level of 249 mg/dL converts to approximately 1.29 g/L or 23.7 mmol/L, which is above the critical threshold of 120 mg/dL (1.2 g/L or 23 mmol/L) used to rule out severe A1AT deficiency. 1

Normal Reference Ranges

  • Normal adult range (M/M phenotype): 100-273 mg/dL 2
  • Severe deficiency threshold: <120 mg/dL 1
  • Your level of 249 mg/dL falls comfortably within the normal range 2

Critical Caveat: When Normal Levels Don't Rule Out Deficiency

You must proceed to DNA sequencing despite this normal level if ANY of the following high-risk features are present: 1, 3

  • Early-onset COPD (before age 40) 1
  • Minimal smoking exposure (<10 pack-years) with COPD 1
  • Panlobular emphysema (especially basilar predominant) 1, 3
  • Family history of COPD or A1AT deficiency 1, 3
  • First-degree relative with confirmed A1AT deficiency 1, 4
  • History of perinatal jaundice 3

Why Normal Levels Can Be Misleading

A1AT is an acute phase reactant that increases during inflammation, potentially masking underlying deficiency. 5 Patients with true A1AT deficiency can show levels as high as 140 mg/dL (1.4 g/L) during acute illness. 1, 5

Rare dysfunctional variants (like Pi*F) produce normal circulating A1AT levels that are non-functional, making serum measurement alone inadequate for diagnosis. 1, 3

Recommended Next Steps

If You Have High-Risk Features:

Proceed directly to DNA sequencing of SERPINA1 gene (exons 2-5) regardless of your normal A1AT level. 1, 3 This is the gold standard test that detects all >300 genetic variants in a single assay. 3

If You Have Moderate-Risk Features Only:

Moderate-risk features include: 3

  • COPD without high-risk features
  • Unexplained bronchiectasis
  • Adult-onset asthma with persistent airflow obstruction
  • Liver cirrhosis
  • ANCA-positive vasculitis

For moderate-risk patients with your level of 249 mg/dL, no further testing is needed at this time unless clinical suspicion remains high. 1

If You Are a First-Degree Relative of Someone with A1AT Deficiency:

You should undergo genetic testing regardless of your normal serum level to determine your carrier status and disease risk. 1, 4 Siblings and offspring of heterozygous individuals have a 25% chance of being heterozygous themselves. 3

Important Testing Pitfalls to Avoid

Do not test during acute illness, active infection, recent surgery, or inflammatory conditions, as these artificially elevate A1AT levels and can mask deficiency. 5, 3 If you were tested during such conditions, repeat testing when clinically stable or proceed directly to genetic testing. 5

Do not rely on repeat serum measurements if clinical suspicion remains high – the test-retest reproducibility of A1AT levels is weak due to biological variability. 1 Genetic mutations are invariant, making DNA sequencing more definitive. 4

Clinical Context

Delayed diagnosis of A1AT deficiency is associated with worse overall survival, reduced transplant-free survival, diminished functional status, and lower quality of life due to the irreversible nature of lung damage. 3 The average diagnostic delay is 5.6 years. 6

A1AT deficiency affects an estimated 1 in 3,000-5,000 individuals in North America, making it one of the most common genetic lung disorders, yet the majority of affected individuals remain undiagnosed. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Laboratory Testing for Alpha-1 Antitrypsin Deficiency

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Alpha-1 Antitrypsin Deficiency Genetics

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Alpha-1 Antitrypsin as an Acute Phase Reactant

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Pathophysiology of Alpha-1 Antitrypsin Lung Disease.

Methods in molecular biology (Clifton, N.J.), 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.